GB0616306D0 - Vaccines - Google Patents

Vaccines

Info

Publication number
GB0616306D0
GB0616306D0 GBGB0616306.7A GB0616306A GB0616306D0 GB 0616306 D0 GB0616306 D0 GB 0616306D0 GB 0616306 A GB0616306 A GB 0616306A GB 0616306 D0 GB0616306 D0 GB 0616306D0
Authority
GB
United Kingdom
Prior art keywords
vaccines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0616306.7A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Priority to GBGB0616306.7A priority Critical patent/GB0616306D0/en
Publication of GB0616306D0 publication Critical patent/GB0616306D0/en
Priority to EP07825522.1A priority patent/EP2073841B1/en
Priority to JP2009524255A priority patent/JP5090452B2/ja
Priority to ES07825522.1T priority patent/ES2528665T3/es
Priority to PCT/IB2007/003255 priority patent/WO2008020328A2/en
Priority to US12/310,188 priority patent/US20100158940A1/en
Priority to CN200780037461.4A priority patent/CN101522217B/zh
Priority to JP2012200460A priority patent/JP2012236864A/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
GBGB0616306.7A 2006-08-16 2006-08-16 Vaccines Ceased GB0616306D0 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
GBGB0616306.7A GB0616306D0 (en) 2006-08-16 2006-08-16 Vaccines
EP07825522.1A EP2073841B1 (en) 2006-08-16 2007-08-15 Manufacture of booster vaccines having reduced antigen doses
JP2009524255A JP5090452B2 (ja) 2006-08-16 2007-08-15 低減された抗原用量を有するブースターワクチンの製造
ES07825522.1T ES2528665T3 (es) 2006-08-16 2007-08-15 Fabricación de vacunas amplificadoras que tienen dosis de antígeno reducidas
PCT/IB2007/003255 WO2008020328A2 (en) 2006-08-16 2007-08-15 Manufacture of booster vaccines having reduced antigen doses
US12/310,188 US20100158940A1 (en) 2006-08-16 2007-08-15 Manufacture of booster vaccines having reduced antigen doses
CN200780037461.4A CN101522217B (zh) 2006-08-16 2007-08-15 抗原剂量降低的加强免疫疫苗的制造
JP2012200460A JP2012236864A (ja) 2006-08-16 2012-09-12 低減された抗原用量を有するブースターワクチンの製造

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0616306.7A GB0616306D0 (en) 2006-08-16 2006-08-16 Vaccines

Publications (1)

Publication Number Publication Date
GB0616306D0 true GB0616306D0 (en) 2006-09-27

Family

ID=37081096

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0616306.7A Ceased GB0616306D0 (en) 2006-08-16 2006-08-16 Vaccines

Country Status (7)

Country Link
US (1) US20100158940A1 (enExample)
EP (1) EP2073841B1 (enExample)
JP (2) JP5090452B2 (enExample)
CN (1) CN101522217B (enExample)
ES (1) ES2528665T3 (enExample)
GB (1) GB0616306D0 (enExample)
WO (1) WO2008020328A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0822633D0 (en) * 2008-12-11 2009-01-21 Novartis Ag Formulation
ES2443952T3 (es) 2009-09-02 2014-02-21 Novartis Ag Composiciones inmunógenas que incluyen moduladores de la actividad de TLR
CN105999275A (zh) 2010-09-01 2016-10-12 诺华有限公司 免疫增强剂吸附不溶性金属离子
US20140112950A1 (en) 2011-03-02 2014-04-24 Manmohan Singh Combination vaccines with lower doses of antigen and/or adjuvant
CN102526717A (zh) * 2011-11-25 2012-07-04 成都康华生物制品有限公司 一种吸附无细胞百白破联合疫苗的制备方法
US9375471B2 (en) * 2012-03-08 2016-06-28 Glaxosmithkline Biologicals Sa Adjuvanted formulations of booster vaccines
US20150125486A1 (en) * 2012-03-08 2015-05-07 Novartis Ag Adjuvanted formulations of pediatric antigens
CN103908667A (zh) * 2014-04-18 2014-07-09 中国医学科学院医学生物学研究所 吸附无细胞百白破-Sabin株脊髓灰质炎联合疫苗及制备方法
CN104707134A (zh) * 2015-03-27 2015-06-17 成都欧林生物科技股份有限公司 一种无细胞百日破联合疫苗及其制备方法
JP6944946B2 (ja) * 2016-10-20 2021-10-06 Ｋｍバイオロジクス株式会社 低分子化ＰＲＰを用いたＨｉｂコンジュゲートワクチンの製造方法
KR102426041B1 (ko) * 2017-08-01 2022-07-29 주식회사 녹십자 냉동 및 해동 과정을 포함하는 백일해균 유래 단백질 수득 방법
WO2020165920A1 (en) * 2019-02-12 2020-08-20 Biological E Limited Multivalent vaccine composition
JP7704740B2 (ja) 2019-09-16 2025-07-08 アムジエン・インコーポレーテツド 薬物送達デバイスの外部滅菌の方法
CN111053898B (zh) * 2019-12-26 2023-05-16 北京科兴中维生物技术有限公司 一种疫苗组合物及其应用
CN114748616A (zh) * 2022-05-23 2022-07-15 中国医学科学院医学生物学研究所 一种成人青少年用无细胞百白破联合疫苗及其制备方法
CN119548620B (zh) * 2025-01-23 2025-09-12 康希诺生物股份公司 一种用于预防白喉、百日咳和破伤风的免疫原性组合物、疫苗及其制备方法和应用
CN119524117B (zh) * 2025-01-23 2025-09-23 康希诺生物股份公司 免疫原性组合物、百白破联合疫苗及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554125A (en) * 1987-07-08 1996-09-10 Reynolds; David L. Prefilled vial syringe
EP2156845A1 (en) * 1992-05-23 2010-02-24 GlaxoSmithKline Biologicals SA Combined vaccines comprising hepatitis B surface antigen and other antigens
US6696065B1 (en) * 1995-05-04 2004-02-24 Aventis Pastuer Limited Acellular pertussis vaccines and methods of preparation thereof
TR199802783T2 (xx) * 1996-07-02 1999-03-22 Connaught Laboratories Limited �ok de�erli DTP polyo a��lar.
US20010014331A1 (en) * 1996-11-07 2001-08-16 Smithkline Beecham Biologicals S.A. Acellular pertussis vaccine with diphthriae-and tetanus-toxoids
GB9623233D0 (en) * 1996-11-07 1997-01-08 Smithkline Beecham Biolog Vaccine composition
ATE316797T1 (de) * 1997-09-15 2006-02-15 Sanofi Pasteur Msd Verfahren zur herstellung multivalenter impfstoffe
EP1004314A1 (fr) * 1998-11-26 2000-05-31 Pasteur Merieux MSD Vaccin T.d. Polio rappel pour une population vaccinée ou sensibilisée
KR100401423B1 (ko) * 2001-01-10 2003-10-17 주식회사 엘지생명과학 혼합 백신의 제조 방법

Also Published As

Publication number Publication date
WO2008020328A3 (en) 2008-06-19
CN101522217A (zh) 2009-09-02
JP5090452B2 (ja) 2012-12-05
JP2010500398A (ja) 2010-01-07
EP2073841B1 (en) 2014-11-26
CN101522217B (zh) 2014-07-16
EP2073841A2 (en) 2009-07-01
US20100158940A1 (en) 2010-06-24
ES2528665T3 (es) 2015-02-11
WO2008020328A2 (en) 2008-02-21
JP2012236864A (ja) 2012-12-06

Similar Documents

Publication Publication Date Title
GB0607088D0 (en) Vaccine
GB0717911D0 (en) Vaccine
GB0711858D0 (en) Vaccine
AP2010005166A0 (en) Vaccines
GB0616306D0 (en) Vaccines
ZA200902155B (en) IPV-DPT vaccine
GB0700135D0 (en) Vaccine
GB0710538D0 (en) Vaccine
ZA200901592B (en) Vaccine
GB0614460D0 (en) Vaccines
GB0709373D0 (en) BCG-based anti-atheroma vaccine
GB0625593D0 (en) Vaccine
GB0621785D0 (en) Vaccines
GB0615115D0 (en) Vaccines
GB0614473D0 (en) Vaccines
GB0601733D0 (en) Vaccines
GB0620160D0 (en) Vaccines
GB0620175D0 (en) Vaccines
GB0614254D0 (en) Vaccine
GB0620815D0 (en) Vaccine
GB0620816D0 (en) vaccine
GB0620337D0 (en) Vaccine
GB0620336D0 (en) Vaccine
GB0619826D0 (en) Vaccine
GB0619824D0 (en) Vaccine

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)